Prediction of 30-Day Mortality Among Patients With
Thrombolysis-Related Intracranial Hemorrhage I ntracranial hemorrhage is the most feared complication of thrombolytic therapy for acute myocardial infarction (AMI). Its frequency in large trials varies from 0.22% to 0.70%, depending in part on the thrombolytic agent used. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Several of these trials have shown mortality rates from this complication of 48% to 74%. [1] [2] [3] [4] [5] [7] [8] [9] [10] [11] [12] [13] [14] [15] Higher doses of the thrombolytic agent, 12, 13 the type of thrombolytic agent used, 4 a larger volume of intracerebral hemorrhage, significant mass effect with midline shift, and multiple bleeding sites 10 have been associated with increased mortality after intracranial hemorrhage in past thrombolytic trials, but such analyses have included relatively few patients with this complication.
In the Global Utilization of Streptokinase and t-PA (alteplase) for Occluded Coronary Arteries (GUSTO-I) trial, 14 268 patients had intracranial hemorrhage. 15 The baseline clinical predictors of 30-day mortality in the entire population have been reported. 16 We wished to develop a model that also incorporated neurological and brain imaging variables to better predict 30-day mortality among patients who experience intracranial hemorrhage after thrombolysis for AMI.
Methods
The GUSTO-I study included 41 021 patients AMI who presented with ST-segment elevation within 6 hours of symptom onset from 1081 hospitals in 15 countries. Descriptions of the entire population, thrombolytic and adjunctive treatments, end points, data management and quality assurance, reporting, and classification of cerebrovascular events have been reported.
14,15

Classification of Intracranial Hemorrhage
Criteria for parenchymal intracerebral hemorrhage, subdural hematoma, intraventricular hemorrhage, and subarachnoid hemorrhage have been published. 6, 12, 13, 15, 17 If multiple lesions or lesion types were present, the most important lesion, clinically speaking, was the largest or the one that best explained the patient's neurological state. The features of each hemorrhagic lesion on brain images were classified centrally by 2 investigators (C.A.S., M.A.S.), as described.
17
Volume and Extent of Lesions
Each lesion was identified by brain imaging and measured by investigators blinded to patient treatment and outcome. 17 A pencil line was drawn around the margin of the lesion on all available brain image slices. For parenchymal intracerebral hemorrhages, 2 methods of volume measurement were used: the modified (greatest vertical height ϫ greatest anterior-posterior extent ϫ greatest medial-lateral extent)/2 method 13,18 -22 or the 3-dimensional stereotactic/planimetric method (proprietary software run on a Sun Microsystems SparcStation), performed by the Center for Computer Assisted Neurosurgery, Department of Neurosurgery, Cleveland Clinic Foundation. For subdural hematomas, volumes were calculated on the basis of a further modification of the first method shown above. 18 -22 The greatest vertical height was calculated as for the intracerebral hemorrhages. The maximum anterior-posterior lesion length was estimated by drawing a straight line between the anterior and posterior borders of the lesion. The medial-lateral extent of the lesion was estimated from the slice portion that showed the greatest distance between the cortical surface and the inner table of the skull. 23 We used the volumes calculated by the 3-dimensional method for all analyses reported here.
Grading of intraventricular hemorrhage and hydrocephalus has been described. 17 The presence of subarachnoid hemorrhage was graded semiquantitatively according to the method of Hijdra et al. 23 Brain edema was defined as the low-density region contiguous to the hematoma. The volume of edema was measured by the 3-dimensional volumetric method-drawing a pencil line around the border of the edema, measuring the volumes of the hematoma and edema, and subtracting hematoma volume from the total. Mass effect was graded according to the degree of ventricular compression and cisternal effacement (ambient cistern, quadrigeminal cistern). The presence and direction of any herniation were recorded: subfalcial, downward, or upward. 
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Clinical Features
Two independent investigators (M.A.S., K.W.M.) retrospectively determined the Glasgow Coma Scale score at the initial evaluation of 202 of the 268 patients with intracranial hemorrhage (75.4%), using all available clinical information. Patients described as being "in coma" or "unresponsive" and who had no additional discriminating information were assigned a score of 7. If seizures were associated with the clinical presentation, the best estimated Glasgow Coma Scale score before the seizure or after complete recovery from the postictal state was used. Agreement between the 2 evaluators was excellent; for the 174 patients classified by both, the median (25th, 75th percentile) absolute difference in scores was 0 (0,1), and the meanϮ SD absolute difference was 1.0Ϯ1.8.
Statistical Analysis
Baseline characteristics were summarized as frequencies and percentages for categorical data and as medians and interquartile ranges for continuous variables. 2 and Fisher's exact tests were used to examine relations between categorical variables, whereas the Wilcoxon rank-sum test was used for continuous variables.
A multivariable logistic regression model 24 examined individual and joint relations between baseline clinical predictors of mortality in the GUSTO-I population, 16 neurological and neuroimaging features, and death within 30 days of randomization for the 268 patients with intracranial hemorrhage during hospitalization. These baseline variables were examined graphically and statistically to assess the assumption that they related linearly to the log-odds of the outcome event (30-day mortality). Adjustments were made for nonlinear relations. We also tested for interactions among the significant variables. Complete data existed for 170 patients (63.4%); these data were used to construct the multivariable outcome prediction model.
Odds ratios and 95% CI for each variable in the full model were computed. For this analysis, total volume was truncated at a lower limit of 50 mL (the 25th percentile) to meet linearity assumptions. The predictive performance of the model was validated with bootstrapping techniques. The model was refitted for each of 50 bootstrap samples (which included samples of the same size as the original population, drawn randomly with replacement from the original sample), then tested on the original sample. This estimates the predictive accuracy of the model if applied to an independent sample of patients. [25] [26] [27] [28] The measure of the model's predictive discrimination was the area under the receiver-operator characteristic curve (the C-index). This curve shows all possible pairwise sensitivity and specificity values for the regression model. The C-index measures the concordance of predictions with actual outcomes 29, 30 ; an area of 1.00 represents a model with perfect discrimination. Calibration of the model was assessed by comparing the average model prediction with the observed mortality rate across deciles of risk. 16 A nomogram was constructed using the coefficients of a simplified version of the 
Results
In 240 patients with intracranial hemorrhage, the most prominent lesion was a parenchymal intracerebral hemorrhage in 197 patients (82.1%), a subdural hematoma in 7 patients (2.9%), and both in 36 patients (15%). The parenchymal intracerebral hemorrhage group included subarachnoid and intraventricular hemorrhages (2 had intraventricular or subarachnoid hemorrhages only). The overall mortality rate from intracranial hemorrhage was 59.7%. Patients who died were older and had intracranial hemorrhage sooner after thrombolysis than those who survived (Tables 1 and 2 ). The median (25th, 75th percentiles) time from treatment to death for the 160 patients with intracranial hemorrhage who died was 54.4 hours (24, 134). The median time from stroke symptom onset to death for these patients was 40.5 hours (12, 116) . Patients with intracranial hemorrhage were more likely to die within 30 days if they had a lower Glasgow Coma Scale score, a combination parenchymal-subdural hematoma, multiple parenchymal intracerebral hemorrhages, or a deep parenchymal intracerebral hemorrhage (especially within the putamen/internal capsule and brain stem; Table 2 ). For other neuroimaging characteristics, the presence of mass effect, herniation, hydrocephalus, and intraventricular hemorrhage were all significantly more common in patients who died. Intraventricular hemorrhage was an independent predictor of 30-day mortality, but there was no relation between intraventricular hemorrhage volume and 30-day mortality (median, 14 mL; interquartile range 4 to 36 mL for patients who died versus 11 mL [5 to 23 mL] for survivors, Pϭ0.56).
Univariable and Multivariable Predictors of Mortality
In univariable analysis, a lower Glasgow Coma Scale score was most strongly associated with 30-day mortality, followed by shorter time from thrombolysis to hemorrhage; larger total hemorrhagic volume; and the presence of hydrocephalus, herniation, or mass effect ( Table 3 ). The baseline clinical predictors of 30-day mortality in the overall GUSTO-I population and location of hemorrhage also were significantly associated with 30-day mortality.
The most significant independent predictors of 30-day mortality (in decreasing order of importance) were time from thrombolysis to hemorrhage, Glasgow Coma Scale score, total hemorrhagic volume, and the GUSTO-I clinical predictors (Table 4) . Because these 4 variables accounted for 93% of the total prognostic information, we developed a reduced version of this model (Table 5 ). Because age was by far the most predictive variable in the overall GUSTO-I model, 16 a simpler model that substituted age alone for the combined "GUSTO-I clinical predictors" yielded similar results ( Table 5) .
The coefficients from the simplified model were used to create a nomogram to predict 30-day mortality in individual patients (Figure 1 ). For an 80-year-old with a Glasgow Coma Scale score of 5 due to an 80-mL intracranial hemorrhage occurring 20 hours after thrombolysis, the estimated probability of 30-day mortality would be 14ϩ16ϩ93ϩ5ϭ128, or Ϸ90%. For a 60-year-old with a Glasgow Coma Scale score of 12 due to a 30-mL intracranial hemorrhage occurring 40 hours after thrombolysis, the estimated probability of 30-day mortality is 7ϩ5ϩ87ϩ0ϭ99, or 7.5%. Figure 2 shows the calibration (reliability) of the full model (Table 4 ). This figure shows the observed 30-day mortality rates across deciles of predicted risk versus the predicted mortality rates of the full multivariable model. The validation of the full model with bootstrapping techniques showed that the C-index was overoptimistic by 0.01, yielding a biascorrected C-index of 0.93.
Discussion
We anticipated that several factors would be highly predictive of 30-day mortality among patients with intracranial hemorrhage after thrombolysis, such as Glasgow Coma Scale score, total intracranial hemorrhage volume, and age. We also discovered a powerful new factor: time from thrombolytic treatment to onset of symptoms of intracranial hemorrhage. With a model that incorporates these and other variables, mortality among these patients can be predicted with a high degree of accuracy. Mortality associated with spontaneous parenchymal intracerebral hemorrhage has been found to vary from 83% for pontine to 16% for subcortical lobar sites. [32] [33] [34] Independent predictors of mortality from spontaneous supratentorial intracerebral hemorrhage have included hemorrhage volume, 19, 20, [35] [36] [37] [38] low Glasgow Coma Scale score, 19, 20, [35] [36] [37] [38] pulse pressure, 35 ,37,38 intraventricular hemorrhage, 35 and an interaction term between intraventricular hemorrhage and Glasgow Coma Scale score. 35 The reported sensitivity, specificity, and accuracy of these models is 62% to 97%, 87% to 97%, and 92%, respectively. 19, 20, 35, 37, 38 These models allow development of highly accurate algorithms to predict 30-day mortality in patients with supratentorial parenchymal hemorrhage, which can aid in the selection of appropriate patients for aggressive medical or surgical treatment. 19, 20, 35, 37, 38 Predictors of increased mortality 30 days after intracranial hemorrhage in GUSTO-I are similar to those of spontaneous supratentorial parenchymal hemorrhage and oral anticoagulant therapy-related intracerebral hemorrhage. Univariable analyses show significant relations between 30-day mortality and GUSTO-I clinical predictors, 16 Glasgow Coma Scale score, hematoma location, hematoma volume, time from thrombolysis to intracranial hemorrhage onset, hydrocephalus, herniation, mass effect, and intraventricular hemorrhage. In fact, the combined parenchymal-subdural lesion was the most ominous, being fatal in 28 of 36 patients (78%). Our results thus confirm and extend the results from the first 3 Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials and the Duke Databank for Cardiovascular Disease. 10 In multivariable analysis, Glasgow Coma Scale score and total hemorrhage volume were independent predictors of 30-day mortality, similar to results reported for spontaneous supratentorial parenchymal hemorrhage. 19, 20, 35, 37, 38 In addition, a shorter time from thrombolysis to intracranial hemorrhage onset was a significant, independent predictor of 30-day mortality. Our data suggest some correlation between shorter time from thrombolysis to intracranial hemorrhage onset and intracranial hemorrhage volume. This implies a temporal link between the biological effects of thrombolysis, clinical concomitants of intracranial hemorrhage, and mortality. Alternatively, mild intracranial hemorrhages may not have been recognized as quickly as were severe ones. Although intracranial hemorrhage volumes were significantly larger in patients treated with combined thrombolytic therapy, 17 this factor was not an independent predictor of mortality. We also found that the baseline clinical predictors of 30-day mortality in the overall GUSTO-I population, especially age, were independently associated with 30-day mortality from intracranial hemorrhage. These 4 factors accounted for 93.1% of the full model's discriminative power. In the simplified model, the larger overall sample size of GUSTO-I and the effects of Glasgow Coma Scale score and hemorrhage volume may have diminished the strong general effect of age on mortality after infarction. 39, 40 Our findings have implications for the management of intracranial hemorrhage after thrombolysis. It is not known whether patients with severe intracranial hemorrhage soon after thrombolytic therapy should receive only supportive medical care 41 or should be aggressively managed (treatment of increased intracranial pressure, ventriculostomy, neurosurgical evacuation). For now, the use of Figure 1 may aid in the clinician's empirical decision-making for such patients.
This study has several limitations. First, the models were derived from a retrospective analysis. Second, the use of best-estimated Glasgow Coma Scale scores may have introduced some misclassification bias. The arbitrary assignment of a Glasgow Coma Scale score of 7 to patients with "coma" or "unresponsiveness" may be considered too conservative, however, thus underestimating its contribution to the model. In addition, the excellent agreement between a cardiologist and a neurologist in independently assigning Glasgow Coma Scale scores suggests that misclassification bias may have been minimized. However, prospective determination of Glasgow Coma Scale scores would have been better. Third, missing data, particularly for Glasgow Coma Scale scores, may have limited the power of the analysis and introduced bias, although the sample size of our multivariable model (nϭ170) compares favorably with those of recent studies of mortality prediction for spontaneous supratentorial parenchymal hemorrhage. 19, 35, 37, 38 Finally, the treating clinician's perception of poor outcome from intracranial hemorrhage may have influenced the decision to provide aggressive support for these patients. As a result, the model reported here may partly reflect the clinician's behavior in treating these patients. This model should be validated in a larger, unselected population. Graph showing observed 30-day mortality after thrombolysisrelated intracranial hemorrhage versus mortality predicted by the full multivariable logistic regression model (Table 4) . Patients were grouped into deciles according to their predicted probability of death. The actual mortality rate for the patients within each decile (dots) is plotted against the average model prediction. The solid line reflects perfect calibration of the model predictors.
